THE ASSOCIATED COSTS OF TREATING TYPE 2 DIABETES PATIENTS TO A CLINICALLY RELEVANT COMPOSITE ENDPOINT WITH LIRAGLUTIDE VERSUS EXENATIDE

被引：0
|
作者：
Langer, J. [1 ]
Bouchard, J. R. [1 ]
机构：
[1] Novo Nordisk Inc, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.954
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A176 / A176
页数：1
相关论文
共 50 条
  • [1] COST ANALYSIS OF TREATMENT SUCCESS TO ACHIEVE A CLINICALLY RELEVANT COMPOSITE ENDPOINT FOR PATIENTS WITH TYPE-2 DIABETES ON LIRAGLUTIDE OR OTHER ANTIDIABETIC THERAPIES IN A CHINESE SETTING
    Shi, L. W.
    Han, S.
    Ploug, U. J.
    Liu, F.
    VALUE IN HEALTH, 2013, 16 (03) : A160 - A161
  • [2] Is liraglutide or exenatide better in type 2 diabetes?
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (16) : 2769 - 2772
  • [3] Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
    Voukali, Maria
    Kastrinelli, Irene
    Stragalinou, Sapfo
    Tasiopoulou, Dimitra
    Paraskevopoulou, Pinelopi
    Katsilambros, Nicholas
    Kokkinos, Alexandros
    Tentolouris, Nicholas
    Ioannidis, Ioannis
    JOURNAL OF DIABETES RESEARCH, 2014, 2014
  • [4] REAL WORLD OUTCOMES IN TYPE 2 DIABETES: LOWER COST OF TREATING PATIENTS TO A1C<7% WITH LIRAGLUTIDE VERSUS EXENATIDE
    Dekoven, M.
    Lee, W. C.
    Bouchard, J. R.
    Massoudi, M.
    Langer, J.
    VALUE IN HEALTH, 2013, 16 (07) : A438 - A438
  • [5] Treatment of Type 2 Diabetes mellitus: Exenatide or Liraglutide?
    Bossenmayer, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (08) : 354 - 354
  • [6] Investigational treatments for Type 2 diabetes mellitus:: exenatide and liraglutide
    Gonzalez, Claudio
    Beruto, Valeria
    Keller, Guillermo
    Santoro, Silvina
    Di Girolamo, Guillermo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (08) : 887 - 895
  • [7] Liraglutide effective in treating type 2 diabetes
    不详
    FORMULARY, 2004, 39 (09) : 432 - 432
  • [8] HEALTH CARE RESOURCE UTILIZATION AND COSTS OF PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. EXENATIDE QW OR LIRAGLUTIDE IN THE US
    Mody, R.
    Alatorre, C.
    Yu, M.
    Lando, Fernandez L.
    Davis, B.
    Juneau, P.
    VALUE IN HEALTH, 2017, 20 (05) : A178 - A178
  • [9] MEDICATION ADHERENCE AND MEDICAL COSTS ASSOCIATED WITH EXENATIDE BID VERSUS LIRAGLUTIDE: A RETROSPECTIVE DATABASE ANALYSIS
    Pelletier, E. M.
    Pawaskar, M.
    Chapman, R.
    VALUE IN HEALTH, 2012, 15 (04) : A179 - A180
  • [10] Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?
    Ling, Charlotte
    DIABETOLOGIA, 2022, 65 (11) : 1849 - 1853
12345